Mike Sharma: Adding Antiplatelets to Anticoagulation in AF Increases Harm Without Benefit
Mike Sharma, Senior Scientist at Population Health Research Institute, reposted from JAMA Neurology on LinkedIn:
”Adding antiplatelets to anticoagulation in the setting of AF results in hazard without benefit. Now we’ll established in multiple studies. Where we lack data is in short term use following a cerebrovascular event that may be atherosclerotic in origin in patients with coexisting AF.”
Quoting JAMA Neurology‘s post:
”Editorial: The ATIS-NVAF trial shows adding antiplatelet therapy to OAC in stroke patients with AF and atherosclerotic disease increases major bleeding without significant reduction in ischemic events.”
Read the full article here.
Title: Anticoagulation and Antiplatelet Therapy in Patients With Atrial Fibrillation and Atherosclerosis
Authors: Richard A. Bernstein, Lauren E. Previch
Stay updated with Hemostasis Today.
-
Jun 25, 2026, 13:45Judith Verlaan: Body Fat Distribution and Its Role in Coagulation and VTE Risk
-
Jun 25, 2026, 13:38Sonal Sonu: Kell VS Rh – Not All Blood Group Systems Affect Erythropoiesis the Same Way
-
Jun 25, 2026, 13:35Mariann Bautista: Simplifying Coagulation Quality Control
-
Jun 25, 2026, 13:31Stéphane Laurent: Key Highlights of ISBT 2026 for INLOG
-
Jun 25, 2026, 13:29Melinda Barkhuizen: When Neurology Meets Hematology – Parkinson’s Disease Genes in Platelets
-
Jun 25, 2026, 10:49Onisillos Sekkides: Quantifying Maternal IgG Against Group B Streptococcus Alpha-Like Proteins in Neonates
-
Jun 25, 2026, 05:26Paola Mendez Hiraldo: Glenn Ruperto’s Stroke Recovery and the Power of Team-Based Care
-
Jun 25, 2026, 05:19Steven Bell: Lessons in Rapid Stroke Care from Vall d’Hebron University Hospital
-
Jun 25, 2026, 04:48Brianne Martin: Stroke Recovery Is More Than Medical Appointments